Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy.
| Autor: | Rezaei MM; Department of Urology, Masshad University of Medical Sciences, Iran., Rezaei MM; Department of Urology, Masshad University of Medical Sciences, Iran., Ghoreifi A; Department of Urology, Masshad University of Medical Sciences, Iran., Kerigh BF; Department of Urology, Masshad University of Medical Sciences, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Canadian Urological Association journal = Journal de l'Association des urologues du Canada [Can Urol Assoc J] 2016 Sep-Oct; Vol. 10 (9-10), pp. E300-E305. Date of Electronic Publication: 2016 Sep 13. |
| DOI: | 10.5489/cuaj.3655 |
| Abstrakt: | Introduction: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT. Methods: In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment. Results: Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six- and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months. Conclusions: Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|